Concord Biotech Limited — Important, 18-07-2025: Updates

Concord Biotech's Active Pharmaceutical Ingredient (API) manufacturing facility in Dholka successfully completed its European Union Good Manufacturing Practice (EU GMP) inspection. This is a crucial operational milestone, reaffirming the company's commitment to stringent quality, safety, and compliance standards. For investors, this ensures continued access to the lucrative European market and strengthens the company's global standing, highlighting its dedication to meeting rigorous international regulatory requirements and supporting future growth prospects.